Risk of falls in patients with cirrhosis evaluated by timed up and go test: Does muscle or brain matter more?

Abstract

BACKGROUND\nMinimal hepatic encephalopathy (MHE) is considered a risk factor for falls in patients with liver cirrhosis. However, MHE is prevalent in patients with muscle alterations (sarcopenia and myosteatosis) probably due to the role of muscle in ammonia handling.\n\n\nAIM\nTo assess the respective role of muscle alterations and MHE on the risk of falls in cirrhotic patients.\n\n\nMETHODS\nFifty cirrhotics were studied for MHE detection by using Psychometric Hepatic Encephalopathy Score (PHES) and Animal Naming Test (ANT). CT scan was used to quantify the skeletal muscle index (SMI) and muscle attenuation, as a measure of myosteatosis. The risk of falls was evaluated by the Timed Up&Go test (TUG). The occurrence of falls during follow up was also detected.\n\n\nRESULTS\n32 patients (64%) had an abnormal TUG (< 14\xa0s). In the group with TUG ≥ 14\xa0s, MHE (72vs31%, p<0.005) and myosteatosis (94vs50%, p\xa0=\xa00.002) were significantly more frequent than in patients with TUG<14\xa0s. At multivariate the variables independently associated to TUG ≥ 14\xa0s were myosteatosis, MHE and chronic beta-blockers use. During a mean follow-up of 25±16.9 months, 12 patients fell; the percentage of falls was significantly higher in patients with TUG ≥ 14\xa0s (50%vs9%, p\xa0=\xa00.001) as well as in patients with myosteatosis (33%vs6%, p\xa0=\xa00.03), but similar in patients with or without MHE (35%vs15%, NS).\n\n\nCONCLUSION\nIn cirrhotic patients both muscle alterations and cognitive impairment, as well as chronic beta-blockers use, are associated to the risk of falls.